## III. Remarks

## (i) Response To Restriction Requirement

In the Office Action, the Examiner issued a Restriction Requirement, and stated that restriction to one of the following inventions is required:

Group I: Claims 1-16, 20-45, drawn to method of treating allergic rhinitus and

chronic idiopathic urticaria comprising administering loratidine

transdermally, and a transdermal delivery device containing loratadine

classified in class 424, subclass 449.

Group II: Claims 17-19, drawn to method of lessening the incidence of side effects

in a patient associated with oral administration of loratadine, classified in

class 424, subclass 449.

In response, Applicants hereby elect, without traverse, Group I, claims 1-16, 20-45, drawn to method of treating allergic rhinitus and chronic idiopathic urticaria comprising administering loratidine transdermally, and a transdermal delivery device containing loratadine classified in class 424, subclass 449.

## (ii) Response to Election Requirement

In response to the election of species requirement under 35 U.S.C. 121, Applicants hereby elect <u>without traverse</u> the following patentably distinct species of the claimed invention:

dosing interval: at least a 3-day dosing interval

the backing layer material: flexible material 4.33

polymer: silicone (1 3 5

208.1004US

This Response is being submitted within 2 (two) months from the mailing date of the Office Action, thus a 1 (one) month extension fee of \$110.00 is enclosed. If it is determined that any additional fees are due or if any fees have been overpaid, the Commissioner is specifically authorized to charge said fee to Deposit Account No. 50-0552.

An early and favorable action on the merits is earnestly solicited.

Respectfully submitted,

DAVIDSON, DAVIDSON & KAPPEL, LLC

Bv

Robert J. Paradisc Reg. No. 41,240

Davidson, Davidson & Kappel, LLC 485 Seventh Avenue, 14<sup>th</sup> floor New York, New York 10018 (212) 736-1940